Stand out stocks included 99 Technology (ASX:NNT) and Bubs (ASX:BUB) (Pic: Getty)
Top Quarterlies: Most stocks have slid today, but these 5 are defying the tide
News
share
As the countdown continues to the next quarterly report filing deadline (this Friday, January 29), Stockhead recaps the best performers.
99 Technology (ASX:NNT)
This stock is a marketing solutions and cloud services provider and is one of the few left from China.
It made $12.17 million in revenue and a $11.94 gross profit in Q4, up 27 per cent and 33 per cent respectively from 2019’s December quarter.
99 Technology also released its 2020 full year results, notching up revenue of $48.79 million and a $46.42 million gross profit.
The company reported market sentiment had softened in this quarter due to sporadic COVID-19 cases in Northern China. Shares in 99 Technology rose nearly 10 per cent today and it is in positive territory over past 12 months.
99 Technology (ASX:NNT) share price chart
Bubs Australia (ASX:BUB)
The dairy product maker also reported challenging market conditions but was able to deliver a solid result.
It’s quarterly gross revenue came in at $12.8 million, up 36 per cent from the September quarter although down 12 per cent from the previous December quarter.
Several of Bubs’ individual market segments did better, including goat dairy products which rose 45 per cent last quarter. Its offtake sales on Chinese ecommerce platforms also rose 163 per cent compared to the prior corresponding period.
It also declared that it was the fastest growing infant formula manufacturer across Woolworths, Coles and Chemist Warehouse.
Bubs Australia (ASX:BUB) ASX share price chart
Impedimed (ASX:IPD)
The medtech stock, which makes medical devices that can track and measure fluids in the body, reported record overall business results with $2.1 million in total revenues.
Of this, $1.9 million came from its SOZO devices, which can assess for secondary lymphedema and deliver doctors of a precise snapshot of a patient’s fluid status and tissue composition, quickly.
It also reported a record number of patient tests for the quarter, notching up 28,000.
Impedimed (ASX:IPD) share price chart
Zebit (ASX:ZBT)
The San Diego-based ecommerce and BNPL player has had a rough start to listed life on the ASX.
But today shares saw a modest boost after it reported record quarterly revenues of US$22.8 million, up 51 per cent from 2019’s December quarter.
It also cut its bad debts from 19.9 per cent to 10.9 per cent.
Zebit’s CEO Marc Schneider declared that his company remained focused on achieving high growth in 2021 and in his years of operating companies he’d “never seen such a strong demand and repeat usage of a product offering”.
Zebit (ASX:ZBT) share price chart
MoneyMe (ASX:MME)
Demand for credit is on the rise and MoneyMe is in the right place at the right time.
The company once again reported record loan originations of $69 million – up 52 per cent from the September quarter with $25 million of that coming in December alone.
It’s closing gross loan book sat at $168.2 million as at 31 December 2020 and was on a trajectory for over $27 million in originations in January.
The company credited its increasing product diversification having launched 3 new products already worth 9 per cent of its book – List Ready, Rent Ready and MoneyMe+ which fund vendor advertising, property expenses for landlords and shopping expenses respectively.
It expects these to be the catalyst for further growth.
